Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.

Tendler S, Grozman V, Lewensohn R, Tsakonas G, Viktorsson K, De Petris L.

Lung Cancer. 2018 Jun;120:75-81. doi: 10.1016/j.lungcan.2018.03.026. Epub 2018 Mar 30.

PMID:
29748020
2.

Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.

Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Hååg P, Bomzon Z, Kirson ED, Weinberg U, Viktorsson K, Lewensohn R, Palti Y.

Radiat Oncol. 2017 Dec 29;12(1):206. doi: 10.1186/s13014-017-0941-6.

3.

Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment.

Eriksson M, Hååg P, Brzozowska B, Lipka M, Lisowska H, Lewensohn R, Wojcik A, Viktorsson K, Lundholm L.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):174-187. doi: 10.1016/j.ijrobp.2017.09.033. Epub 2017 Sep 22.

PMID:
29107335
4.

Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer.

Tsakonas G, Hellman F, Gubanski M, Friesland S, Tendler S, Lewensohn R, Ekman S, de Petris L.

Acta Oncol. 2018 Feb;57(2):231-238. doi: 10.1080/0284186X.2017.1386799. Epub 2017 Oct 6.

PMID:
28984492
5.

Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment.

Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R, Zhivotovsky B.

Oncogene. 2017 Aug 17;36(33):4818. doi: 10.1038/onc.2017.78. Epub 2017 Apr 10.

PMID:
28394341
6.

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Nyman J, Hallqvist A, Lund JÅ, Brustugun OT, Bergman B, Bergström P, Friesland S, Lewensohn R, Holmberg E, Lax I.

Radiother Oncol. 2016 Oct;121(1):1-8. doi: 10.1016/j.radonc.2016.08.015. Epub 2016 Sep 3.

PMID:
27600155
7.

Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.

Efazat G, Novak M, Kaminskyy VO, De Petris L, Kanter L, Juntti T, Bergman P, Zhivotovsky B, Lewensohn R, Hååg P, Viktorsson K.

Oncotarget. 2016 Sep 13;7(37):60332-60347. doi: 10.18632/oncotarget.11219.

8.

Preclinical activity of melflufen (J1) in ovarian cancer.

Carlier C, Strese S, Viktorsson K, Velander E, Nygren P, Uustalu M, Juntti T, Lewensohn R, Larsson R, Spira J, De Vlieghere E, Ceelen WP, Gullbo J.

Oncotarget. 2016 Sep 13;7(37):59322-59335. doi: 10.18632/oncotarget.11163.

9.

Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells.

Zovko A, Novak M, Hååg P, Kovalerchick D, Holmlund T, Färnegårdh K, Ilan M, Carmeli S, Lewensohn R, Viktorsson K.

Oncotarget. 2016 Aug 2;7(31):50258-50276. doi: 10.18632/oncotarget.10361.

10.

91P: Validation of the 7th and upcoming 8th TNM staging system in small cell lung cancer.

Tendler S, Lewensohn R, Viktorsson K, de Petris L.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S96. doi: 10.1016/S1556-0864(16)30204-0. Epub 2016 Apr 15. No abstract available.

11.

Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.

Viktorsson K, Shah CH, Juntti T, Hååg P, Zielinska-Chomej K, Sierakowiak A, Holmsten K, Tu J, Spira J, Kanter L, Lewensohn R, Ullén A.

Mol Oncol. 2016 May;10(5):719-34. doi: 10.1016/j.molonc.2015.12.013. Epub 2016 Jan 2.

12.

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J.

Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10.

PMID:
26553306
13.

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.

Gréen H, Hasmats J, Kupershmidt I, Edsgärd D, de Petris L, Lewensohn R, Blackhall F, Vikingsson S, Besse B, Lindgren A, Brandén E, Koyi H, Peterson C, Lundeberg J.

Clin Cancer Res. 2016 Jan 15;22(2):366-73. doi: 10.1158/1078-0432.CCR-15-0964. Epub 2015 Sep 16.

14.

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines.

Salim H, Zong D, Hååg P, Novak M, Mörk B, Lewensohn R, Lundholm L, Viktorsson K.

BMC Cancer. 2015 Sep 9;15:628. doi: 10.1186/s12885-015-1635-9.

15.

Toward Rare Blood Cell Preservation for RNA Sequencing.

Vickovic S, Ahmadian A, Lewensohn R, Lundeberg J.

J Mol Diagn. 2015 Jul;17(4):352-9. doi: 10.1016/j.jmoldx.2015.03.009. Epub 2015 May 16.

PMID:
25989392
16.

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer.

Johansson HJ, Sanchez BC, Forshed J, Stål O, Fohlin H, Lewensohn R, Hall P, Bergh J, Lehtiö J, Linderholm BK.

Clin Proteomics. 2015 Mar 21;12(1):8. doi: 10.1186/s12014-015-9080-y. eCollection 2015.

17.

Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience.

Lindberg K, Nyman J, Riesenfeld Källskog V, Hoyer M, Lund JÅ, Lax I, Wersäll P, Karlsson K, Friesland S, Lewensohn R.

Acta Oncol. 2015;54(8):1096-104. doi: 10.3109/0284186X.2015.1020966. Epub 2015 Mar 27.

PMID:
25813471
18.

Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasets.

Skripcak T, Belka C, Bosch W, Brink C, Brunner T, Budach V, Büttner D, Debus J, Dekker A, Grau C, Gulliford S, Hurkmans C, Just U, Krause M, Lambin P, Langendijk JA, Lewensohn R, Lühr A, Maingon P, Masucci M, Niyazi M, Poortmans P, Simon M, Schmidberger H, Spezi E, Stuschke M, Valentini V, Verheij M, Whitfield G, Zackrisson B, Zips D, Baumann M.

Radiother Oncol. 2014 Dec;113(3):303-9. doi: 10.1016/j.radonc.2014.10.001. Epub 2014 Oct 28. Review.

19.

Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma.

Zovko A, Viktorsson K, Hååg P, Kovalerchick D, Färnegårdh K, Alimonti A, Ilan M, Carmeli S, Lewensohn R.

Mol Cancer Ther. 2014 Dec;13(12):2941-54. doi: 10.1158/1535-7163.MCT-14-0329. Epub 2014 Oct 15.

20.

Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma.

Shah CH, Viktorsson K, Kanter L, Sherif A, Asmundsson J, Rosenblatt R, Lewensohn R, Ullén A.

Urol Oncol. 2014 Nov;32(8):1215-24. doi: 10.1016/j.urolonc.2014.04.015. Epub 2014 May 28.

PMID:
24880461
21.

Systems biology approaches to develop innovative strategies for lung cancer therapy.

Viktorsson K, Lewensohn R, Zhivotovsky B.

Cell Death Dis. 2014 May 29;5:e1260. doi: 10.1038/cddis.2014.28. Review.

22.

Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.

Lundholm L, Hååg P, Juntti T, Lewensohn R, Viktorsson K.

Int J Radiat Biol. 2014 Aug;90(8):718-26. doi: 10.3109/09553002.2014.905725. Epub 2014 Jun 25.

PMID:
24646078
23.

Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer.

Zong D, Zielinska-Chomej K, Juntti T, Mörk B, Lewensohn R, Hååg P, Viktorsson K.

Cell Death Dis. 2014 Mar 13;5:e1111. doi: 10.1038/cddis.2014.56.

24.

miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.

Salim H, Arvanitis A, de Petris L, Kanter L, Hååg P, Zovko A, Özata DM, Lui WO, Lundholm L, Zhivotovsky B, Lewensohn R, Viktorsson K.

Genes Chromosomes Cancer. 2013 Oct;52(10):895-911. doi: 10.1002/gcc.22085. Epub 2013 Aug 9.

PMID:
23929716
25.

Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism.

Pernemalm M, De Petris L, Branca RM, Forshed J, Kanter L, Soria JC, Girard P, Validire P, Pawitan Y, van den Oord J, Lazar V, Påhlman S, Lewensohn R, Lehtiö J.

J Proteome Res. 2013 Sep 6;12(9):3934-43. doi: 10.1021/pr4002096. Epub 2013 Aug 13.

26.

APS8, a polymeric alkylpyridinium salt blocks α7 nAChR and induces apoptosis in non-small cell lung carcinoma.

Zovko A, Viktorsson K, Lewensohn R, Kološa K, Filipič M, Xing H, Kem WR, Paleari L, Turk T.

Mar Drugs. 2013 Jul 16;11(7):2574-94. doi: 10.3390/md11072574.

27.

A role for Myh1 in DNA repair after treatment with strand-breaking and crosslinking chemotherapeutic agents.

Jansson K, Alao JP, Viktorsson K, Warringer J, Lewensohn R, Sunnerhagen P.

Environ Mol Mutagen. 2013 Jun;54(5):327-37. doi: 10.1002/em.21784. Epub 2013 May 16.

PMID:
23677513
28.

Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.

Patel C, Stenke L, Varma S, Lindberg ML, Björkholm M, Sjöberg J, Viktorsson K, Lewensohn R, Landgren O, Gottesman MM, Gillet JP.

Cancer. 2013 Aug 15;119(16):3076-83. doi: 10.1002/cncr.28098. Epub 2013 May 14.

29.

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N, Richardson P, Lewensohn R, Anderson KC.

Clin Cancer Res. 2013 Jun 1;19(11):3019-31. doi: 10.1158/1078-0432.CCR-12-3752. Epub 2013 Apr 12.

30.

Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.

Shah CH, Viktorsson K, Sherif A, Kanter L, Grybäck P, Lewensohn R, Sandström P, Nilsson S, Ullén A.

Anticancer Drugs. 2013 Jul;24(6):648-52. doi: 10.1097/CAD.0b013e328360c1c3.

PMID:
23542751
31.

Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery.

Beskow C, Agren-Cronqvist AK, Lewensohn R, Toma-Dasu I.

J Contemp Brachytherapy. 2012 Dec;4(4):205-12. doi: 10.5114/jcb.2012.32554. Epub 2012 Dec 28.

32.

Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.

Lundholm L, Hååg P, Zong D, Juntti T, Mörk B, Lewensohn R, Viktorsson K.

Cell Death Dis. 2013 Jan 31;4:e478. doi: 10.1038/cddis.2012.211.

33.

Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412.

Ståhl S, Kaminskyy VO, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, Moshfegh A, Lewensohn R, Viktorsson K, Zhivotovsky B.

Cell Death Dis. 2013 Jan 10;4:e454. doi: 10.1038/cddis.2012.188.

34.

Validation of the 7th TNM classification for non-small cell lung cancer: a retrospective analysis on prognostic implications for operated node-negative cases.

Bergman P, Brodin D, Lewensohn R, de Petris L.

Acta Oncol. 2013 Aug;52(6):1189-94. doi: 10.3109/0284186X.2012.742960. Epub 2012 Dec 7.

PMID:
23215828
35.

miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence.

Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, Viktorsson K, Zhivotovsky B.

Br J Cancer. 2012 Oct 9;107(8):1361-73. doi: 10.1038/bjc.2012.382. Epub 2012 Aug 28.

36.

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.

Masucci GV, Wersäll P, Kiessling R, Lundqvist A, Lewensohn R.

J Transl Med. 2012 May 22;10:104. doi: 10.1186/1479-5876-10-104.

37.

Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy.

Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, Lewensohn R, Wersäll P.

Radiother Oncol. 2011 Nov;101(2):260-6. doi: 10.1016/j.radonc.2011.09.012. Epub 2011 Nov 5.

PMID:
22056534
38.

Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair.

Malewicz M, Kadkhodaei B, Kee N, Volakakis N, Hellman U, Viktorsson K, Leung CY, Chen B, Lewensohn R, van Gent DC, Chen DJ, Perlmann T.

Genes Dev. 2011 Oct 1;25(19):2031-40. doi: 10.1101/gad.16872411.

39.
40.

Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.

Ståhl S, Branca RM, Efazat G, Ruzzene M, Zhivotovsky B, Lewensohn R, Viktorsson K, Lehtiö J.

J Proteome Res. 2011 May 6;10(5):2566-78. doi: 10.1021/pr200037u. Epub 2011 Apr 11.

PMID:
21413766
41.

NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction.

Wennberg BM, Baumann P, Gagliardi G, Nyman J, Drugge N, Hoyer M, Traberg A, Nilsson K, Morhed E, Ekberg L, Wittgren L, Lund JÅ, Levin N, Sederholm C, Lewensohn R, Lax I.

Acta Oncol. 2011 May;50(4):518-27. doi: 10.3109/0284186X.2010.543695. Epub 2011 Jan 4.

PMID:
21198416
42.

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer.

De Petris L, Brandén E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehtiö J.

Eur J Cancer. 2011 Jan;47(1):131-7. doi: 10.1016/j.ejca.2010.08.006. Epub 2010 Sep 6.

PMID:
20822898
43.

A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants.

De Petris L, Pernemalm M, Elmberger G, Bergman P, Orre L, Lewensohn R, Lehtiö J.

Proteome Sci. 2010 Feb 26;8:9. doi: 10.1186/1477-5956-8-9.

44.

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.

Wickström M, Viktorsson K, Lundholm L, Aesoy R, Nygren H, Sooman L, Fryknäs M, Vogel LK, Lewensohn R, Larsson R, Gullbo J.

Biochem Pharmacol. 2010 May 1;79(9):1281-90. doi: 10.1016/j.bcp.2009.12.022. Epub 2010 Jan 11.

PMID:
20067771
45.

Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86.

Beskow C, Skikuniene J, Holgersson A, Nilsson B, Lewensohn R, Kanter L, Viktorsson K.

Br J Cancer. 2009 Sep 1;101(5):816-21. doi: 10.1038/sj.bjc.6605201. Epub 2009 Aug 11.

46.

Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion.

Pernemalm M, De Petris L, Eriksson H, Brandén E, Koyi H, Kanter L, Lewensohn R, Lehtiö J.

Proteomics. 2009 Jul;9(13):3414-24. doi: 10.1002/pmic.200800814.

PMID:
19609957
47.

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, Lewensohn R.

Ann Oncol. 2009 Oct;20(10):1639-46. doi: 10.1093/annonc/mdp062. Epub 2009 Jun 23.

PMID:
19549711
48.

Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.

Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L.

Exp Hematol. 2009 Jun;37(6):755-66. doi: 10.1016/j.exphem.2009.03.002.

PMID:
19463775
49.

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R.

J Clin Oncol. 2009 Jul 10;27(20):3290-6. doi: 10.1200/JCO.2008.21.5681. Epub 2009 May 4.

PMID:
19414667
50.

Metabolomics: moving to the clinic.

Nordström A, Lewensohn R.

J Neuroimmune Pharmacol. 2010 Mar;5(1):4-17. doi: 10.1007/s11481-009-9156-4. Epub 2009 Apr 28. Review.

PMID:
19399626

Supplemental Content

Loading ...
Support Center